1. Home
  2. MIRM vs HLN Comparison

MIRM vs HLN Comparison

Compare MIRM & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$81.92

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Logo Haleon plc (Each representing two)

HLN

Haleon plc (Each representing two)

HOLD

Current Price

$10.07

Market Cap

44.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
HLN
Founded
2018
2022
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
44.5B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
HLN
Price
$81.92
$10.07
Analyst Decision
Strong Buy
Hold
Analyst Count
11
1
Target Price
$95.64
N/A
AVG Volume (30 Days)
891.8K
9.2M
Earning Date
02-25-2026
02-26-2026
Dividend Yield
N/A
1.77%
EPS Growth
N/A
41.64
EPS
N/A
0.23
Revenue
$471,794,000.00
$15,096,588,575.00
Revenue This Year
$53.78
$1.51
Revenue Next Year
$19.91
$4.67
P/E Ratio
N/A
$21.71
Revenue Growth
53.66
N/A
52 Week Low
$36.88
$8.71
52 Week High
$82.58
$11.42

Technical Indicators

Market Signals
Indicator
MIRM
HLN
Relative Strength Index (RSI) 64.14 57.04
Support Level $73.82 $9.88
Resistance Level $82.58 $10.31
Average True Range (ATR) 3.65 0.12
MACD 0.31 0.01
Stochastic Oscillator 89.31 51.00

Price Performance

Historical Comparison
MIRM
HLN

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About HLN Haleon plc (Each representing two)

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Share on Social Networks: